Telix Pharmaceuticals in focus with China trial success and FDA updates

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today after the company released an update on its precision medicine portfolio, highlighting positive Phase 3 results for Illuccix in China and progress on key FDA regulatory resubmissions.

What did Telix Pharmaceuticals report?

• Positive Phase 3 trial results for Illuccix (TLX591-CDx) in Chinese prostate cancer patients, with an impressive 94.8% patient-level positive predictive value (PPV).
• The Illuccix China study met its primary endpoint and enabled near-term New Drug Application (NDA) submission in China.
• FDA resubmission for TLX101-CDx is close to finalisation following productive discussions.
• Progress on addressing FDA chemistry, manufacturing, and controls (CMC) concerns for TLX250-CDx, with further meetings scheduled.
• Ongoing Expanded Access Programs (EAPs) for TLX101-CDx and TLX250-CDx support continued patient access.

What else do investors need to know?

The Illuccix study in China included 140 prostate cancer patients and showed the PSMA-PET imaging agent delivered strong results even at low PSA levels. More than 67% of patients had a change in their treatment plan due to the study, underlining Illuccix’s clinical impact.

For TLX101-CDx and TLX250-CDx, Telix is taking steps to address FDA requirements for approval and remains confident about their potential. Both programs have active expanded access pathways, keeping treatment options open for eligible patients.

What did Telix Pharmaceuticals management say?

Dr David N. Cade, Group Chief Medical Officer, stated:

This is an outstanding result. The primary endpoint of the study was met decisively, with the positive predictive value significantly exceeding the performance threshold agreed with the Chinese regulator. Importantly, the high PPV was consistent even in patients with very low PSA values, and across differing metastatic locations, demonstrating broad clinical applicability. These compelling data will enable Telix and our partner Grand Pharma to submit a New Drug Application for Illuccix in China, a strategically important market.

What’s next for Telix Pharmaceuticals?

Telix plans to submit a New Drug Application for Illuccix in China, opening doors to a major growth market where the need for advanced prostate cancer imaging is rising. The company is also working with the FDA to resolve outstanding matters for TLX101-CDx and TLX250-CDx, aiming for future regulatory approvals.

Investors should keep an eye on near-term updates regarding U.S. regulatory filings and expansion into new markets. Telix’s commitment to patient access and clinical innovation will likely shape its growth in the months ahead.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix Pharmaceuticals shares have declined 52%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 5% over the same period.

View Original Announcement

The post Telix Pharmaceuticals in focus with China trial success and FDA updates appeared first on The Motley Fool Australia.

More reading

• Aurizon lodges new 10-year network access undertaking with QCA
• These are the 10 most shorted ASX shares
• Stockland announces estimated 1H26 distribution
• Champion Iron launches $289m Rana Gruber takeover: what shareholders need to know
• NEXTDC lifts contracted utilisation and order book in December update

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.